Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome.
Diabetes Care
; 31(2): 363-5, 2008 Feb.
Article
em En
| MEDLINE
| ID: mdl-17959865
ABSTRACT
OBJECTIVE:
We sought to compare mortality reduction associated with secondary prevention in patients with and without diabetes after acute coronary syndrome (ACS). RESEARCH DESIGN ANDMETHODS:
We conducted a cohort study involving 2,499 patients with ACS recruited from 11 U.K. hospitals. Multivariable analysis comparing all-cause mortality risk reduction associated with pharmacologic agents in patients with and without diabetes.RESULTS:
Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0.50-1.08); nondiabetic patients derived a 48% mortality reduction (P < 0.001). The interaction between diabetes and aspirin use was statistically significant (P = 0.037), indicating that patients with diabetes experience less effective mortality reduction from aspirin use.CONCLUSIONS:
Aspirin, but not other secondary prevention agents, is associated with less effective mortality reduction in patients with diabetes and unstable coronary artery disease.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Inibidores da Agregação Plaquetária
/
Aspirina
/
Angiopatias Diabéticas
/
Síndrome Coronariana Aguda
Tipo de estudo:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article